PACB Pacific Biosciences of California Inc.

PacBio to Present at Upcoming Investor Conferences

PacBio to Present at Upcoming Investor Conferences

MENLO PARK, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:

  • Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 8:45 AM ET in New York, NY
  • 46th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 11, 2025, at 10:40 AM ET in Miami Beach, FL

Live webcasts of the events can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcasts will be available for at least 30 days following the event.

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Contacts

Investors:

Todd Friedman

Media:



EN
28/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacific Biosciences of California Inc.

 PRESS RELEASE

PacBio Announces Second Quarter 2025 Financial Results

PacBio Announces Second Quarter 2025 Financial Results MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2025. Second quarter results:  Q2 2025Q2 2024Revenue$39.8 million$36.0 millionInstrument revenue$14.2 million$14.7 millionConsumable revenue$18.9 million$17.0 millionService and other revenue$6.7 million$4.3 millionRevio™ systems1524Vega™ systems38—Annualized Revio pull-through per system~$219,000~$251,000Cash, cash equivalents, and investments$314.7 million$509.8 million Gross margin, operating...

 PRESS RELEASE

PacBio to Present at Upcoming Investor Conferences

PacBio to Present at Upcoming Investor Conferences MENLO PARK, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 2:30 PM ET in Boston, MAMorgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at 12:20 PM ET in New York, NY Live webcasts of the events can be accessed at the company’s in...

 PRESS RELEASE

Nature Methods Paper Leverages PacBio Sequencing Technology to Develop...

Nature Methods Paper Leverages PacBio Sequencing Technology to Develop the Platinum Pedigree Benchmark, a New Standard for Accurate Characterization of Variation in the Human Genome that Improves Training for AI Models The most comprehensive, family-based variant dataset ever published will improve variant classification using AI-based tools MENLO PARK, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced the results of describing a new, comprehensive truth-set of genomic variation whi...

 PRESS RELEASE

PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in...

PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications Study reveals millions of previously unknown variants and genomic sequences from underrepresented populations MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a significant advancement for global genomic equity. Researchers have published the first Arab human pangenome in , powered in large part by PacBio’s HiFi long-read sequencing. The study, led by Mohammed Bin Rashid Univers...

 PRESS RELEASE

PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequenc...

PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio New Iso-Seq data from ~1,000 samples to expand transcriptomic insights using highly accurate HiFi sequencing MENLO PARK, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced it has joined the 1000 Genomes Long Read Sequencing Project, which will involve contributing long-read transcriptome data to one of the world’s most expansive human genomics initiatives. In collaboration with the laborat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch